Search This Blog

Saturday, May 16, 2026

Media Lies About Obamacare And Medicaid Debunked

 The news stories are pretty much all the same. Heartless Republicans slashed Medicaid spending and let temporary “enhanced” Obamacare subsidies expire, and now millions are losing health insurance.

But buried deep within those stories, if it’s there at all, is the fact that when measured properly, enrollment for both programs is up.

Here’s a prime example.

Axios this week ran a story with the headline “Health program cuts hit home, fueling blame game.”

It begins by saying that “Sweeping changes that congressional Republicans made to the Affordable Care Act and Medicaid are starting to take effect, fueling an election-year blame game over coverage losses” and that enrollment in Obamacare is down 1.2 million from last year.

It goes on to say that 20,000 people could lose Medicaid coverage in Nebraska alone thanks to the new work requirements included in the One Big Beautiful Bill Act.

It’s only buried at the bottom of that story that Axios admits the truth:

Obamacare “enrollment will likely still be well above the numbers from before the enhanced subsidies were first passed in 2021, when there were around 12 million enrollees,” it grudgingly admits.

(Why isn’t that the headline?)

Even then, Axios leaves out the fact that those “enhanced subsidies,” passed by Democrats and signed by Joe Biden, were meant to be a temporary salve in the wake of COVID. Enrollment was always supposed to come back down.

The same is true with Medicaid. During COVID, states were banned from cleaning their enrollment rolls. The result was that enrollment exploded. Once that ban was lifted, states started cleaning up their rolls, and the numbers started to decline.

And while today’s news reports blare claims that millions will lose coverage, the truth is that the number of enrollees today is still higher than it was in 2020, before the massive COVID expansion.

Even though new Medicaid work requirements will thin enrollment somewhat going forward, in a decade it’s still forecast to be 73 million, which is higher than any time in the program’s history before 2016.

What’s more, the current enrollment forecast is in line with projections made before COVID, according to data from the Congressional Budget Office.

Of course, the lie at the center of all these stories is that the bigger the enrollment in Medicaid and Obamacare, the better. The truth is that the ideal enrollment in these programs is zero. Because that would mean nobody is dependent on government to cover the cost of health insurance.

https://issuesinsights.com/2026/05/14/media-lies-about-obamacare-and-medicaid-debunked/

Billions for Medicaid Expansion Congress Never Approved

 The Biden administration may have failed to convince Congress to double Medicaid spending on home healthcare in 2021, but the funding increase occurred anyway.

An RCI analysis of federal data has found that spending on the program, which pays health aides and family members to act as caregivers for elderly and disabled adults, nearly doubled between 2019 and 2024, to $46.4 billion a year – an amount nearly identical to the $50 billion per year Biden wanted. As a result, American taxpayers paid more than $217 billion for home-based care under the program during that five-year span.

RCI

Lacking congressional approval, policymakers simply moved the initiative out of Washington and down to the state Medicaid agencies. 

Although the expansion was promoted as a way to reduce reliance on more expensive nursing homes, federal data show that did not happen. Medicaid spending on nursing facilities rose by nearly $5 billion in the same five years, to $46.3 billion. In addition, the sprawling home care program has become the subject of a growing set of fraud probes and prosecutions involving the billing codes at the center of the new spending.

The data suggest that the complex landscape of healthcare offers myriad ways for states and providers to access large amounts of federal funding. 

Promises

The spending boom traces back to a March 2021 White House proposal. As part of its American Jobs Plan, the Biden administration called for $400 billion in new federal spending over eight years to expand home and community-based care under Medicaid. “President Biden believes more people should have the opportunity to receive care at home, in a supportive community, or from a loved one,” the White House said in its rollout.

Advocacy groups had long sought a vast expansion of home care. AARP told policymakers that home- and community-based services would “prevent or delay frail seniors and persons with disabilities from being admitted to nursing homes,” and that the cost would be a fraction of facility-based care – about $1,300 per person per year for community support against $25,000 to $37,000 per year for a Medicaid nursing-home bed. Justice in Aging, a national legal advocacy organization focused on older adults, said nursing home care was four times more expensive than community-based services and that older adults without home-care access were five times more likely to enter a nursing home.

The federal government put a number on the projected savings. The Department of Health and Human Services’ Office of the Assistant Secretary for Planning and Evaluation projected that for every additional dollar Medicaid spent on home care, nursing-home spending would drop by about 26 cents. Those were the figures used to make the case to Congress and to the public.

Justice for Aging and the Department of Health and Human Services did not respond to requests for comment.

Congress Unconvinced

AP
President Joe Biden's proposal for a vast expansion of home care was never passed by Congress but the funding flowed anyway. 

Congress was not convinced. The home-care expansion was cut to $150 billion in the Build Back Better Act, which did not win passage and then dropped entirely from the Inflation Reduction Act, which Biden signed into law in 2022.

Much of the money was spent anyway. When federal legislation stalled, the mechanism for delivering funding shifted from Congress to state Medicaid agencies. The Centers for Medicare and Medicaid Services worked with state programs to expand existing waivers, raise reimbursement rates paid to home-care providers, and build out programs that pay family members to act as caregivers. States that wanted to grow their spending pulled the regulatory levers they already had. States that hesitated were offered federal matching dollars, technical assistance, and a steady drumbeat of CMS guidance encouraging them to expand.

By 2024, Medicaid spending on the home-health bundle – personal-care services, home health aides, skilled nursing in the home, and the related billing codes that capture the bulk of the dollars – was $22 billion higher per year than in 2019. That increase amounted to roughly 44% of the annual expansion the Biden White House had originally sought from Congress, achieved without Congress ever approving the program.

Blue State Windfall

Most of the dollars were accessed by Democratic-controlled states. New York alone reached $15.67 billion in Medicaid home-health spending by 2024 – roughly a third of the national total – through its Consumer Directed Personal Assistance Program, which allows beneficiaries to hire a relative as the paid caregiver. Massachusetts, New Jersey, Illinois, California, and Pennsylvania all rank in the top tier of absolute spending growth. Pennsylvania’s home-health bill grew more than twelvefold over five years.

The fastest percentage growth between 2019 and 2024 came in Republican-controlled states with smaller base programs. Texas grew its Medicaid home-health spending by 330%. Arkansas grew by 352%. Alabama, 250%. Spending rose in every state in the union.

These numbers may grow due to lengthening waiting lists for people seeking home-care services. According to a Kaiser Family Foundation analysis of state Medicaid agency data, the number of Americans on waiting lists for Medicaid home- and community-based services has risen rather than fallen since 2019, despite the $217 billion expansion. Advocates say this is a reflection of the growing need for such services.

As the home-care proponents predicted, the number of Medicaid beneficiaries actually living in nursing homes did fall during the five-year period. Unique Medicaid nursing home users went from 1.57 million in 2019 to 1.29 million in 2023, a 17.7% decline. Most of the drop happened during the pandemic, when COVID-19 swept through nursing facilities and prompted admissions freezes at many homes in 2020 and 2021. Since 2021, the Medicaid nursing home population has been climbing again.

Rising Prices

But this did not produce savings, as states sharply increased the rates they paid to facilities. Medicaid spending on nursing homes grew from $41.4 billion in 2019 to $46.3 billion in 2024. The cost per resident per day at Medicaid-certified nursing facilities climbed from $313.66 in 2019 to $401.98 in 2024, a 28% increase.

RCI

The same dynamic occurred with reimbursements for home care. State Medicaid agencies raised home-care reimbursement rates sharply during and after the pandemic – 15% to 30% in many states – and most of those increases were never rolled back. 

The official justification was a workforce shortage. The claims-level data show a different pattern. While Medicaid spending on home health grew 91% over five years, the number of providers billing Medicaid for these services barely grew, and the number of unique beneficiaries grew only modestly. What climbed each year was the price per claim and the price per beneficiary.

The larger share bought expanded eligibility – programs designed to enroll people who would not otherwise have entered a nursing home. The clearest example is New York’s Consumer Directed Personal Assistance Program, which allows the Medicaid beneficiary to hire a relative as the paid caregiver. According to a claims-level analysis of CMS Transformed Medicaid Statistical Information System (T-MSIS) data, the New York program grew from a niche state option into the single largest line item in Medicaid home-care spending nationally.

The total number of people involved in the program is hard to discern because federal claims data do not separate individual family caregivers from agency providers. In a self-directed Medicaid program such as home-care, the beneficiary – not an agency – picks and hires the caregiver, and the state pays that caregiver directly. The caregiver is most often a family member, a friend, or a neighbor. In states with large self-directed programs, the count of paid family caregivers is likely to be in the tens of thousands of individuals. State enrollment standards for self-directed and family caregivers were also relaxed during the pandemic, with documentation requirements reduced and licensing barriers lowered to expand the workforce.

Fraud Magnet

The expansion has become a documented vehicle for fraud. The U.S. Department of Justice and the HHS Office of Inspector General have brought a growing number of prosecutions involving the T1019 personal-care billing code – including fraudulent hours never worked, billing for deceased beneficiaries, and family-member billing schemes in which the care was either never delivered or was billed at a fraction of the claimed hours.

In December 2024, Pennsylvania Attorney General Michelle Henry announced charges against a suburban Philadelphia home-care agency, its owner, and 18 other people in a scheme that allegedly defrauded the state’s Medicaid program out of millions of dollars. The Department of Justice’s Health Care Fraud Unit listed multiple home-health prosecutions in its 2025 national case summaries.

AP
Vice President JD Vance said he's directing the Federal Fraud Task Force to examine home-care spending.

The Daily Wire’s recent investigation of Ohio’s multi-billion-dollar home-care industry found a lack of oversight. “Since the services are performed inside private residences, there is no way to know whether the workers went at all, or what they’re actually doing in exchange for taxpayer funds,” Luke Rosiak reported. “An infinite number of small black boxes inside a black box. Multiple signs said the service provided, and billed to the government, was sometimes just ‘companionship & conversation.’”

Even as Ohio says it has ongoing probes into its home-care spending and Vice President JD Vance announced he’s directing the federal Fraud Task Force he heads to examine the Buckeye State, RCI’s analysis suggests a deeper problem – the extent to which massive federal dollars can flow without congressional approval. 

Budget hawks say fraud must be addressed, but even that does not address the underlying mechanisms – massive funding with relatively little oversight – that invite runaway spending and abuse. The recent history of home-care funding also highlights the often false premises on which many government programs are sold to the American people.

Walter Curt is a Senior Fellow at Restoration of America and the founder of The W.C. Dispatch. Follow him on X at @wcdispatch and at wcdispatch.com.

https://www.realclearinvestigations.com/articles/2026/05/14/unbridled_spending_billions_for_medicaid_program_congress_never_approved_1182576.html?mc_cid=c84364dbbc&mc_eid=0622ebfa37

Anthropic joins Gates Foundation on $200m health AI pledge

 AI company Anthropic and the Gates Foundation have said they will provide $200 million in funding for a programme to support the development of AI for "health, life sciences, education, and economic mobility" over the next four years.

In health and life sciences, the focus is on developing tools that can improve health outcomes in low- and middle-income countries, where 4.6 billion people lack access to health services, to support the development of new vaccines and therapeutics, and help governments use health data to inform policy decisions.

The programme will be able to draw support from Anthropic in terms of access to technical staff and usage credits for its Claude AI platform – accounting for around half the value of its commitment – while the Gates Foundation will provide funding and help direct where the funding should be allocated.

Anthropic will also develop 'connectors', which grant Claude direct access to other platforms and tools, along with benchmarks, and evaluation frameworks that will "allow researchers, developers, and governments to better understand how AI systems perform on healthcare-related tasks."

In a statement, the Gates Foundation said AI remains out of reach for billions of people around the world, with many of the most powerful models remaining "concentrated among those with the most resources," and closing that gap "requires designing with equity as the goal." Any tools generated by the effort will be made freely available.

Anthropic, meanwhile, said it sees the commitment as central to its efforts to "extend the benefits of AI in areas where markets alone will not."

Specific projects envisioned by the partners include using Claude to ramp up research on high-burden and neglected diseases, exploring how AI can make it faster and easier for scientists to screen potential vaccine candidates and potential drugs for HPV and preeclampsia, and a partnership with the Gates Foundation's the Institute for Disease Modeling (IDM) to improve the forecasts that determine where and how treatments for diseases like malaria and tuberculosis are deployed.

The company has made expanding its operations into the healthcare and life sciences sectors a priority, which was strengthened a few weeks ago when it appointed Novartis chief executive Vas Narasimhan to its board.

It has also cemented its position in AI-powered drug discovery with the recent acquisition of Coefficient Bio, while several pharma companies – including Novo Nordisk, AstraZeneca, Sanofi, AbbVie, and Genmab – are using Claude for Life Sciences in their business operations.

Earlier this year, the Gates Foundation also announced a $50 million alliance with OpenAI to support country-led efforts – called Horizon1000 and starting in Rwanda – to explore how AI tools can help reduce the burden on clinicians, improve quality of care, and reach more patients.

The goal is to reach 1,000 primary healthcare clinics and their surrounding communities by 2028.

https://pharmaphorum.com/news/anthropic-joins-gates-foundation-200m-health-ai-pledge

Amgen Statement on TAVNEOS® (avacopan)

 On May 15, 2026, media outlets reported 20 deaths associated with patients being treated with TAVNEOS® (avacopan) in Japan. The report was based on a regulatory notification in Japan and lacked important context. Amgen believes it is important to provide that context for the benefit of clinicians and patients.

Kissei, which owns the rights to TAVNEOS in Japan, reported 20 fatal cases of serious liver injury, from over 8,500 patients who have been treated with TAVNEOS in Japan. These figures include cases for which a causal relationship with the product could not be determined.

There have been no known deaths in the U.S. linked to serious liver injury, including vanishing bile duct syndrome (VBDS), in the more than 8,000 patients in the U.S. treated with TAVNEOS.

TAVNEOS is an important and effective medicine that treats anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. ANCA-associated vasculitis (AAV) is a rare and serious disease in which the immune system attacks blood vessels and can damage major organs. Severe AAV can be life-threatening, with five-year mortality rates over 20%. Without treatment, mortality rates may exceed 90% after the first year. Even with treatment, many patients face ongoing health problems and major impacts on daily life.

Since the U.S. approval in 2021, the U.S. prescribing information has included reference to the risk of serious liver injury (hepatotoxicity) and has provided specific liver monitoring guidance for physicians and patients. Amgen continuously reviews global safety data and shares updated information with the FDA.

Amgen acquired Chemocentryx in 2022, a year after the product launched in the U.S. and currently holds U.S. rights for TAVNEOS. Vifor Fresenius Medical Care Renal Pharma (now CSL-Vifor) acquired ex-US commercial rights to TAVNEOS in 2016 from Chemocentryx. Kissei obtained exclusive rights for TAVNEOS in Japan from Vifor in 2017.

Interactions with regulatory agencies, clinicians and patients outside the U.S are handled by the companies that have ownership rights for the medicine in those jurisdictions.

Based on all available data, Amgen continues to believe TAVNEOS demonstrates effectiveness and a favorable benefit–risk profile for patients living with AAV. Amgen continues to engage with the FDA regarding TAVNEOS. Our focus remains on patient safety, patient needs, and ongoing support for the AAV community.

https://www.amgen.com/newsroom/company-statements/amgen-statement-on-tavneos

Regeneron Phase 3 in first-line unresectable or metastatic melanoma misses primary endpoint

 Regeneron Phase 3 fianlimab plus cemiplimab trial in first-line unresectable or metastatic melanoma misses primary endpoint of progression-free survival vs pembrolizumab

https://finviz.com/quote?t=REGN&p=d

https://www.marketscreener.com/news/good-timing-to-anticipate-the-return-of-volatility-ce7f5bd2dc8ff521

https://www.marketscreener.com/news/volatility-should-make-a-big-comeback-ce7f5bd2dc8ff32d